# Benchlight Science — full text

> Benchlight Science is a reader-focused publication about the vocabulary used in biotechnology and life-science research. It helps students, curious readers, and non-specialists understand what a term means, how researchers use it, and what the evidence can actually support.

# Biological vs. Technical Replicates: What n Counts

> Biological replicates measure biologically distinct samples; technical replicates repeat measurements of the same sample. The distinction helps separate biological variation from measurement variation, but neither label alone establishes the independent experimental unit or the correct statistical sample size. Read the design, figure legend, and analysis together. These explanations support research literacy, not interpretation of personal test results or treatment decisions, which belong with a qualified clinician.

Source: https://biotimeinc.com/biological-vs-technical-replicates/  
Publisher: Benchlight Science  
Published: 2026-09-08  
Updated: 2026-09-08

## What is the difference between biological and technical replicates?

Biological replicates measure biologically distinct samples to describe biological variation. Technical replicates repeat measurements of the same sample to describe measurement variation. Neither label, by itself, identifies the independent unit used in a statistical analysis. When reading a paper, ask what was repeated, what each plotted point represents, and what the reported sample size counts. This is research literacy, not guidance for interpreting personal tests or choosing treatment.

The distinction matters because twelve readings can come from twelve biological sources, or from one source measured twelve times. Those arrangements answer different questions even when a graph gives them the same number of dots.

## What does each kind of replicate tell you?

The [NIH training discussion on biological and technical replicates](https://www.grants.nih.gov/policy/reproducibility/training/biological-technical-rep.pdf) distinguishes biologically distinct samples from repeated measurements of one sample. The former capture biological variation; the latter address random variation associated with equipment or measurement procedures.

| Reading question | Biological replication | Technical replication |
| --- | --- | --- |
| What differs? | The biological samples being compared | Repeated measurements of the same sample |
| What variation is being described? | Variation across those biological samples | Variation in the measurement process |
| What detail must be reported? | The sources and how they are related | What step was repeated and on what material |
| What should not be assumed? | That every sample is an independent experimental unit | That more readings mean more biological sources |

The labels are a starting vocabulary, not a substitute for the methods. A paper might also use "independent replicate," "experimental replicate," or "inter-run replicate." Read the authors' definitions before treating those phrases as interchangeable.

## Why does the experimental unit matter?

The National Centre for the Replacement, Refinement and Reduction of Animals in Research, abbreviated NC3Rs, defines the experimental unit through independent assignment to experimental groups. Its DRIVER guidance distinguishes that unit from the biological entity of interest and the observational unit on which measurements are made.

NC3Rs goes further than simply asking authors to label biological and technical replicates: it recommends using these more explicit unit descriptions because the replicate labels can obscure a design. It also identifies pseudoreplication as treating non-independent measurements as though they were independent. [NC3Rs experimental-unit guidance](https://nc3rs.org.uk/3rs-resources/driver-recommendations/experimental-unit).

For the reader, the practical question is: "Independent for which comparison?" Four donors do not automatically establish an experimental sample size of four for every possible design or inference. Treatments may be assigned at another level, and samples may be paired, clustered, or repeatedly measured. Those relationships need to remain visible in the analysis.

## Can twelve measurements represent only four biological samples?

Yes. Consider this entirely fictional reading exercise. It is not an actual study, assay protocol, reference range, or clinical dataset.

Assume four independently sampled donors each supplied one specimen. Each specimen received three repeated readings of the same measurement. The exercise's question is descriptive: how do the four donor-level summaries differ? There is no treatment comparison.

| Donor specimen | Reading 1 | Reading 2 | Reading 3 | Arithmetic mean |
| --- | --- | --- | --- | --- |
| A | 9 | 10 | 11 | 10 |
| B | 19 | 20 | 21 | 20 |
| C | 29 | 30 | 31 | 30 |
| D | 39 | 40 | 41 | 40 |

All values are invented arbitrary signal units. They have no diagnostic meaning.

There are 4 × 3 = 12 readings, but four donor specimens. In this simplified example, the three readings within each row are technical repeats. The four rows represent the biologically distinct samples.

For A, the mean is (9 + 10 + 11) ÷ 3 = 10. The other row means are 20, 30, and 40. Each row's readings span two units, while the donor means span 40 − 10 = 30 units. These are descriptive ranges, not estimates of population variability or evidence of a clinical difference.

A plot of the four row means would contain four points. A plot of all twelve readings would contain twelve. Changing the display does not create eight additional donors.

## How would you describe that figure accurately?

A clear caption for the fictional example could say:

> Four independent donor specimens were each measured three times. Each plotted point is one specimen's arithmetic mean across its three readings. There are four donor-level summary points and twelve underlying measurements. No inferential statistical test is presented.

The caption explains the hierarchy instead of leaving "n = 12" to carry several possible meanings. It also tells the reader what the displayed points summarize.

The arithmetic mean is used here to make the counting visible. It is not a universal instruction to average every technical repeat in every real study. The actual measurement scale, quality-control rules, study design, and planned analysis determine how data should be handled.

If you encounter a figure with twelve dots but only "experiments performed in triplicate" underneath, record what remains unknown. Were there four sources, four runs, or four experimental conditions? A confident answer cannot be recovered from the word "triplicate" alone.

## Does repeating the work on another day make it biological replication?

Not automatically. The [Assay Guidance Manual's reporting chapter](https://www.ncbi.nlm.nih.gov/sites/books/NBK550206/) uses an additional category, inter-run replicates, for measurements across different runs or experiments. It explicitly cautions that terminology differs across disciplines and that the optimal replication depends on the scientific question.

Use a two-column reading note: "What changed?" and "What stayed the same?" A later date belongs in the first column. Whether the same source material was used belongs in the second question; the date does not answer it.

For example, if the fictional specimens A through D were read again, the report would need to describe that second set of readings and its relationship to the first. It should not silently rename the same four donors as eight donors.

Likewise, a new plate, file, image, or graph panel is not enough information to establish biological independence. Ask where its material came from.

## What if some readings are missing?

Keep the different counts separate before interpreting the result. Suppose the fictional dataset loses one reported reading from specimen D. There would be eleven available readings across four donor specimens, with two readings reported for D and three for each other specimen.

That statement is only an inventory. It does not establish whether D passes the study's quality-control criteria or should be included in an analysis.

If the entire D specimen were absent instead, the displayed dataset would contain three donor specimens and nine readings. The difference between those two situations matters: a missing measurement and a missing biological source are not the same event.

Look for the authors' explanation of exclusions, missing values, and the count used for each analysis. Do not fill missing values yourself or discard a result because it looks inconvenient. For a real research project, unresolved analytical decisions belong with the research team and a qualified statistician.

## What should a figure legend disclose?

[Nature Communications' reproducibility guidance](https://www.nature.com/documents/Biological_and_technical_replicates_guidelines.pdf) asks authors to define what "n" represents accurately in figure legends. It also warns against presenting technical replicates as biological ones.

Use this editorial reading card alongside the figure:

- **Source:** What biological material or population supplied the data?
- **Assignment:** If there was an intervention, what was independently assigned?
- **Measurement:** What exactly produced one recorded value?
- **Point:** Does one dot mean a donor, specimen, repeated reading, or summary?
- **Count:** How many of each are present, and did exclusions change the counts?
- **Analysis:** How were related measurements handled?
- **Uncertainty:** What do any error bars represent?

The Assay Guidance Manual emphasizes naming both the type and number of replicates and identifying error bars. Do not infer their meaning from their length.

The question being measured also matters. A [biomarker](/what-is-a-biomarker/) is not automatically a direct clinical outcome. Clear replication can strengthen the interpretation of a measurement without changing what that measurement represents.

## Is there a universal minimum number of replicates?

No single number resolves every research question. The Assay Guidance Manual explicitly describes the choice as dependent on the question, methods, and sources of variation, and recommends statistical consultation.

For readers, "the study used three" and "three was adequate for this purpose" are different claims. Look for the rationale rather than borrowing a number from an unrelated paper.

The research model also limits interpretation. [In vitro and in vivo](/in-vitro-vs-in-vivo/) describe settings, not automatic guarantees of human relevance. Counting the replicates correctly does not turn an isolated laboratory observation into evidence that a treatment works for a patient.

A useful final reading note is a sentence you can complete without guessing: "The study measured this outcome in these biological sources, repeated these steps, and analyzed these units." If the paper does not provide enough information, mark the gap. Our [research methods collection](/research-methods/) follows that same boundary between what a report states and what its reader might be tempted to assume.

## Sources

- [NIH: biological and technical replicates training discussion](https://www.grants.nih.gov/policy/reproducibility/training/biological-technical-rep.pdf).
- [NC3Rs: DRIVER recommendations on the experimental unit](https://nc3rs.org.uk/3rs-resources/driver-recommendations/experimental-unit).
- [Assay Guidance Manual: basic guidelines for reporting non-clinical data](https://www.ncbi.nlm.nih.gov/sites/books/NBK550206/).
- [Nature Communications: biological and technical replicates guidance](https://www.nature.com/documents/Biological_and_technical_replicates_guidelines.pdf).

## Frequently asked questions

**Are three measurements always three biological replicates?**

No. Three readings of the same specimen can be technical repeats rather than three biologically distinct samples. The number alone does not describe the source or independence of the data. Check what was repeated and what each plotted point represents before interpreting a figure's reported sample size.

**Does four donors always mean n equals four?**

No. Four donors identifies a biological-source count, not the experimental unit for every design or inference. Treatment assignment, pairing, clustering, and repeated measurements may change the analytical structure. A report must identify the units relevant to its particular comparison instead of relying on the donor count alone.

**Does repeating an assay on another day create new biological samples?**

A different day does not, by itself, establish different biological sources. The report should explain whether it reused the same specimens or prepared new material and how runs were related. Keep the number of runs separate from the source count when recording what a study actually describes.

**Should technical replicates always be averaged?**

No universal averaging rule follows from the label. The worked example uses row means only to demonstrate counting. Real handling depends on the measurement scale, quality-control criteria, study design, and planned analysis. Unresolved decisions in a research project should be reviewed with the research team and a qualified statistician.

**Can a well-replicated laboratory result guide my treatment?**

Correct replication does not establish that a laboratory finding applies to an individual patient or demonstrates clinical benefit. The model, measurement, and appropriate human evidence still matter. Use this terminology to read research more carefully, and discuss personal tests, diagnosis, or treatment questions with a qualified clinician.


---

# In Vitro vs. In Vivo: What Each Term Means

> In vitro research is performed in a laboratory outside the body, such as work with cultured cells or a cell-free reaction. In vivo research occurs within a living body or intact organism. The labels describe experimental settings, not a quality ranking. Each result applies first to the model, material, measurements, and conditions actually studied, so neither term alone establishes that the same effect will occur in people.

Source: https://biotimeinc.com/in-vitro-vs-in-vivo/  
Publisher: Benchlight Science  
Published: 2026-07-19  
Updated: 2026-09-07

## What Is the Difference Between In Vitro and In Vivo?

**In vitro** means work done in the laboratory, outside the body. **In vivo** means work done in the body or within a living organism. The terms describe the experimental setting; they do not rank one result as automatically better than the other.

The Latin gives you a location tag, not a quality score. A careful reader still needs to ask what material was studied, how the experiment was designed, and how far its conclusion can travel.

## In Vitro vs. In Vivo at a Glance

| Question | In vitro | In vivo |
|---|---|---|
| Where does it happen? | Outside the body, in a laboratory system | In a living body or intact organism |
| What might be studied? | Cultured cells, tissue components, or a cell-free reaction | A process or response within a living organism |
| What context is present? | A deliberately selected and controlled part of biology | Interacting systems operating in the living organism |
| What does the result establish? | What happened in that laboratory model under its stated conditions | What happened in the stated living model under its conditions |

Neither label tells you whether a study was well designed or whether its result applies to another organism or setting.

## What Does In Vitro Mean in Practice?

The [National Cancer Institute definition](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/in-vitro) is compact: in vitro means in the laboratory, outside the body. A cell-culture experiment is a familiar example, but the exact usage can vary by discipline.

The NCBI Bookshelf chapter from *Molecular Biology of the Cell* explains that cell biologists often call experiments on cultured cells in vitro. Biochemists may use the term more narrowly for reactions in a test tube without living cells. That is why the methods section matters more than the label.

Working outside a whole organism can let researchers observe cells continuously and change selected conditions, such as adding or removing a molecule. This helps separate a particular question from much of the surrounding biological complexity. The trade-off is built into that advantage: an isolated system does not contain every interaction present in an intact organism.

## What Does In Vivo Mean in Practice?

The [National Cancer Institute definition](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/in-vivo) gives the direct contrast: in vivo means in the body. In research writing, identify which living organism or system the authors mean. “In vivo” does not, on its own, mean a study in humans.

An in vivo model keeps biological interactions that an isolated system may omit. It also makes the result harder to attribute to one simple mechanism, because many processes operate together. The setting can answer a broader question, but the conclusion still belongs to the organism, population, measurements, and conditions actually studied.

If a paper tracks a [biomarker](/what-is-a-biomarker/), for example, the model tells you where that measurement was observed. It does not turn the marker into a diagnosis, a clinical outcome, or proof that the same response will occur in people.

## Where Does Ex Vivo Fit?

**Ex vivo** means outside the living body. The [NCI dictionary's medical-procedure definition](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/ex-vivo) describes an organ, cells, or tissue taken from a living body for a treatment or procedure and then returned to the body.

The label alone does not tell you the preservation method, duration, or whether material was returned. Check how the authors define the sample and what they did with it.

## How Should You Read These Labels in a Study?

Use the label as the first line of a short checklist:

1. **Model:** Was the work cell-free, cell-based, tissue-based, or performed in a living organism?
2. **Source:** Which species, tissue, cell type, or participant group supplied the material?
3. **Conditions:** What environment, timing, dose, or exposure did the researchers specify?
4. **Comparison:** What control or reference condition made the result interpretable?
5. **Outcome:** What did the experiment actually measure?
6. **Boundary:** Which conclusion follows directly, and which proposed next step still needs testing?

Our [biotech basics section](/biotech-basics/) applies the same habit to terms such as biomarker: define the noun, then inspect the job it performs in that particular study.

An in vitro finding can be useful without predicting a whole-organism result. An in vivo finding can be useful without establishing an effect in humans. Good research programs often use different models for different questions; good reading keeps each answer attached to the question that produced it.

## Sources

- [National Cancer Institute — In Vitro](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/in-vitro): plain-language definition of research performed in the laboratory outside the body.
- [National Cancer Institute — In Vivo](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/in-vivo): plain-language definition of work performed in the body.
- [National Cancer Institute — Ex Vivo](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/ex-vivo): definition and medical-procedure context for material handled outside a living body.
- [NCBI Bookshelf — *Molecular Biology of the Cell*: Isolating Cells and Growing Them in Culture](https://www.ncbi.nlm.nih.gov/books/NBK26851/): cultured-cell examples and the discipline-dependent use of in vitro and in vivo.

## Frequently asked questions

**Is in vivo research always done in humans?**

No. In vivo means within a living body or organism; it does not identify the species. An in vivo study may involve an animal model, a person, or another living system described by the researchers. Check the methods for the organism, population, conditions, and outcome before deciding how directly the result bears on a human question.

**Is in vivo research more reliable than in vitro research?**

Not automatically. In vitro work can isolate a question under controlled laboratory conditions, while in vivo work includes interactions present in a living organism. Either can be well or poorly designed. Reliability depends on the methods, controls, measurements, and reproducibility; relevance depends on whether the model fits the question being asked.

**What does ex vivo mean?**

Ex vivo means outside the living body. The National Cancer Institute's medical-procedure definition describes an organ, cells, or tissue taken from a living body for a treatment or procedure and then returned. The label alone does not supply every methods detail, so check what was removed, how it was maintained, and whether it was returned.

**Can an in vitro result prove that a treatment works in people?**

No. An in vitro result shows what happened in the stated laboratory model under its stated conditions. It may justify further research, but it does not by itself establish a clinical effect in people. Human treatment decisions require appropriate clinical evidence and professional interpretation; a cell or test-tube result should not be used as personal medical advice.


---

# Positive vs. Negative Controls: What Each Checks

> In a laboratory assay, a positive control has an expected detectable response; a negative control has an expected absence of the target response or a defined baseline. Together, they help researchers check particular aspects of a measurement. Their meaning depends on the method and comparison. They do not prove every conclusion in a study or interpret a personal test result; clinical questions belong with the responsible clinician.

Source: https://biotimeinc.com/positive-vs-negative-controls/  
Publisher: Benchlight Science  
Published: 2026-09-15  
Updated: 2026-09-15

## What is the difference between positive and negative controls?

In a laboratory assay, a positive control has an expected detectable response; a negative control has an expected absence of the target response or a defined baseline. Together, they help researchers check particular aspects of a measurement. Their meaning depends on the method and comparison. They do not prove every conclusion in a study or interpret a personal test result; clinical questions belong with the responsible clinician.

An assay is a procedure used to measure or detect something. When reading its results, ask what each control was intended to establish before deciding what the unknown samples mean.

## What question does each control answer?

The [RIPOSTE research-design framework](https://pmc.ncbi.nlm.nih.gov/articles/PMC4461852/) distinguishes analytical controls, which check laboratory processes, from comparison groups used to answer a study's research question. A known reference sample and a group receiving an established treatment can both be called a positive control, while performing different jobs.

| Control role | Reading question | What to find in the paper |
|---|---|---|
| Positive analytical control | Could the procedure produce its expected positive result? | Known material and expected response |
| Negative analytical control | What appeared where the target response was not expected? | Control composition and observed result |
| Study comparison group | What condition was the experimental group compared with? | Treatment, allocation and comparison being made |

Write the role beside the label. “Compared with the control” is incomplete if the reader cannot identify which control the sentence means.

## Does negative mean zero, and positive mean a high number?

Not necessarily. In the [Assay Guidance Manual's in vivo chapter](https://www.ncbi.nlm.nih.gov/books/NBK92013/?report=reader), a negative control provides a minimally effective comparison, while a positive control can establish a maximally effective reference response. These are roles within the specified assay, not universal numerical values.

The same chapter cautions that controls at the extremes may not describe measurement variability in the middle of the assay's range. Passing two endpoints therefore does not establish equally good performance everywhere between them.

Read the measured outcome and its direction. “Positive control” is not a promise that every graph will show its tallest bar in that group. The method must explain what response was expected.

## Is a no-template control the same as a negative sample?

The distinction is particularly clear in quantitative polymerase chain reaction, or qPCR. The [MIQE 2.0 reporting guidelines](https://academic.oup.com/clinchem/article/71/6/634/8119148) describe positive controls containing the target sequence, negative controls lacking that sequence but containing background nucleic acid, and no-template controls lacking sample nucleic acid. These check different possibilities.

A no-template control helps reveal contamination or artifacts; it does not represent every property of a sample containing other biological material. Read the authors' exact control description. Do not infer a result's validity from the abbreviation alone or transfer a decision rule from another assay.

## Can a control check one problem while missing another?

Yes. Immunohistochemistry uses antibodies to help locate target molecules in tissue. The [Histochemical Society's standards](https://pmc.ncbi.nlm.nih.gov/articles/PMC4212362/) describe positive controls with a known target in its expected location. An internal control is within the specimen; an external control is a separate specimen.

The standards also identify a frequent overclaim: omitting the primary antibody can check nonspecific binding of the secondary antibody, but does not establish that the primary antibody specifically recognizes the intended target. “No staining in the control” needs its full experimental context.

This is a useful reading habit beyond that example: name the alternative explanation being checked. A control should receive credit for the question it addresses, without silently being promoted into proof against every possible error.

## What happens when a control behaves unexpectedly?

Look for the method's acceptance rules and the authors' account of what happened. Do not erase an inconvenient control result or decide independently that the unknown samples remain interpretable.

For a concrete, bounded example, [FDA's immunohistochemistry guidance](https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/guidance-submission-immunohistochemistry-applications-food-and-drug-administration-final-guidance) describes invalid specimen results when the positive tissue control fails to stain, or when specific staining appears in the negative external tissue control. It assigns clinical interpretation to a qualified pathologist. These are statements about that method, not a universal rule for every experiment.

Researchers should follow their validated method and laboratory quality procedures. Readers should record an unresolved limitation rather than inventing a correction.

## How can you keep the interpretation precise?

Try this fictional reading note, which describes no real experiment:

“The report names a positive reference and a negative reference. It states their expected behavior but does not show their observed results. I can identify the intended checks, but cannot establish from this report whether those checks passed.”

That note distinguishes a missing report from a demonstrated failure. It also avoids treating the presence of a control's name as evidence of its performance.

Use a short reading card:

- What material or condition served as the control?
- Which part of the procedure did it check?
- What result was expected, and what was observed?
- Were the acceptance rules stated?
- Which conclusion depends on that check?

Keep related questions separate. [Replicates](/biological-vs-technical-replicates/) concern what was repeated; [in vitro and in vivo](/in-vitro-vs-in-vivo/) identify experimental settings. Neither label supplies the missing control information. Our [research methods collection](/research-methods/) helps connect those descriptions while keeping their limits visible.

## Sources

- [RIPOSTE: laboratory research design and analytical controls](https://pmc.ncbi.nlm.nih.gov/articles/PMC4461852/)
- [Assay Guidance Manual: In Vivo Assay Guidelines](https://www.ncbi.nlm.nih.gov/books/NBK92013/?report=reader)
- [MIQE 2.0: qPCR reporting guidelines](https://academic.oup.com/clinchem/article/71/6/634/8119148)
- [Histochemical Society: controls for immunohistochemistry](https://pmc.ncbi.nlm.nih.gov/articles/PMC4212362/)
- [FDA: immunohistochemistry application guidance](https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/guidance-submission-immunohistochemistry-applications-food-and-drug-administration-final-guidance)

## Frequently asked questions

**Must a negative control produce a value of zero?**

No. In the Assay Guidance Manual's in vivo example, the negative control supplies a minimally effective comparison rather than a universal zero. The reported outcome, measurement scale and expected behavior determine the interpretation. Read that definition before treating a number as evidence that the control passed or failed.

**Can a no-template control replace every negative control?**

No. A no-template control lacks sample nucleic acid, while other negative controls may contain biological background material. They therefore do not represent identical conditions. Check which control the paper actually reports and what it was intended to assess; a short label does not settle every possible source of error.

**What is the difference between internal and external controls?**

In the immunohistochemistry example, an internal positive control is a known target location within the specimen, while an external positive control is a separate specimen. The terms describe where the reference is located. Other methods require their own definitions, so read the methods before transferring that description to a different assay.

**What should I conclude if a control fails?**

Look for the assay's acceptance rules and the laboratory's explanation rather than attempting your own correction. FDA's immunohistochemistry guidance identifies specified tissue-control failures that invalidate specimen results. The implication depends on the method and failure. Personal clinical results should be discussed with the responsible clinician or laboratory, not reinterpreted from a general guide.

**Does including a control prove the study's conclusion?**

No. A control addresses a defined comparison or check; its name alone does not show what happened. In a reading note, separate what the report states from what remains unreported. Ask which conclusion depends on the control, whether its result is available, and whether the authors explain unresolved limitations.


---

# What Is a Biomarker? Seven Types in Plain English

> A biomarker is a defined, measurable characteristic used as an indicator of a normal biological process, a disease process, or a response to an exposure or intervention. Biomarkers may be molecular, histologic, radiographic, or physiologic. Their meaning depends on the stated role, population, sample, analytical method, and context of use; a biomarker is not automatically a diagnosis or a direct measure of how a person feels, functions, or survives.

Source: https://biotimeinc.com/what-is-a-biomarker/  
Publisher: Benchlight Science  
Published: 2026-07-19  
Updated: 2026-09-07

## What Is a Biomarker?

A biomarker is a defined, measurable characteristic used as an indicator of a biological process, a disease process, or a response to an exposure or intervention. It may be molecular, histologic, radiographic, or physiologic. The useful question is not simply “What was measured?” but “What is this measurement meant to indicate in this setting?”

That definition comes from the FDA-NIH Biomarkers, EndpointS, and other Tools resource, usually shortened to BEST. It keeps the term broader than “blood test” and narrower than “anything we can count.” A scan feature, tissue characteristic, gene variant, or physiological measurement can be a biomarker when it has a defined indicator role.

A biomarker is a job description, not a fancy synonym for a laboratory result.

## What Are the Seven Biomarker Categories?

The [U.S. Food and Drug Administration](https://www.fda.gov/drugs/biomarker-qualification-program/about-biomarkers-and-qualification) lists seven BEST categories. The category describes what the marker is being used to do, so the same measured characteristic may have different roles in different contexts.

| Category | What the biomarker indicates |
|---|---|
| [Susceptibility or risk](https://www.ncbi.nlm.nih.gov/books/NBK402288/) | The potential to develop a disease or condition in someone who does not currently have it clinically. |
| [Diagnostic](https://www.ncbi.nlm.nih.gov/books/NBK402285/) | The presence of a disease or condition, or a particular subtype. |
| [Monitoring](https://www.ncbi.nlm.nih.gov/books/NBK402282/) | Status measured repeatedly over time, including disease status or evidence of an exposure or effect. |
| [Prognostic](https://www.ncbi.nlm.nih.gov/books/NBK402289/) | The likelihood of a future clinical event, recurrence, or progression in people who already have the condition of interest. |
| [Predictive](https://www.ncbi.nlm.nih.gov/books/NBK402283/) | Which individuals are more likely to have a favorable or unfavorable effect from a medical product or environmental agent. |
| [Pharmacodynamic or response](https://www.ncbi.nlm.nih.gov/books/NBK402286/) | That a biological response, beneficial or harmful, occurred after an exposure to a medical product or environmental agent. |
| [Safety](https://www.ncbi.nlm.nih.gov/books/NBK402287/) | The likelihood, presence, or extent of toxicity after exposure to a medical product or environmental agent. |

These labels can overlap. A measurement repeated during a study may be a monitoring biomarker, while its particular purpose could also make it a safety or response biomarker. Read the stated role rather than assigning a category from the marker's name alone.

## What Information Makes a Biomarker Claim Useful?

The FDA says a full biomarker description includes the biomarker's name, its source or matrix, the characteristic being measured, and the analytical method. In plain English: what, from where, and measured how.

Then look for the context of use:

- **Population:** Who or what was studied?
- **Purpose:** Was the marker used for diagnosis, monitoring, prediction, safety, or another defined role?
- **Timing:** Was it measured once, repeatedly, before an exposure, or after one?
- **Method:** Which assay, scan, or other analytical procedure produced the value?
- **Decision boundary:** What interpretation was supported, and under which conditions?

This is also where [research-model language](/in-vitro-vs-in-vivo/) matters. A biomarker observed in cultured cells answers a question about that experimental system. It does not automatically carry the same interpretation in a living organism or a person.

Our [research methods section](/research-methods/) focuses on those context clues because a precise noun can still sit inside an overconfident sentence.

## Is a Biomarker the Same as a Clinical Outcome?

No. The FDA's definition says a biomarker is not a direct assessment of how a person feels, functions, or survives. A clinical outcome assessment and a biomarker therefore answer different questions.

Some response biomarkers are used as surrogate endpoints in trials, but “biomarker” does not mean “proven substitute for a clinical benefit.” BEST defines a surrogate endpoint as a biomarker used in place of a direct measure of how a patient feels, functions, or survives, with an expectation that it predicts benefit or harm based on evidence. The context and validation matter.

## What Does FDA Qualification Mean?

In the FDA's drug-development program, qualification means a biomarker has gone through a formal regulatory process for a specific interpretation and application within a stated context of use. The FDA also makes a useful distinction: the biomarker is qualified, not automatically every method that might measure it.

Qualification is therefore not a universal stamp for every population, assay, or purpose. When reading a claim, check the exact context instead of letting the word “qualified” do more work than the evidence.

For a personal test result, the relevant interpretation depends on the test, units, reference information, health context, and reason it was ordered. That question belongs with the clinician responsible for the test, not a general terminology guide.

## Sources

- [FDA — About Biomarkers and Qualification](https://www.fda.gov/drugs/biomarker-qualification-program/about-biomarkers-and-qualification): BEST definition, characteristic types, seven categories, full biomarker descriptions, context of use, and qualification scope.
- [FDA-NIH Biomarker Working Group — BEST Resource](https://www.ncbi.nlm.nih.gov/books/NBK326791/): formal category definitions, overlap between roles, response biomarkers, and the distinction between biomarkers and surrogate endpoints.

## Frequently asked questions

**Is every laboratory test result a biomarker?**

Not simply because it was measured. Under the FDA-NIH BEST definition, a biomarker is a defined characteristic measured as an indicator of a biological or disease process, or a response to an exposure or intervention. A useful description identifies the characteristic, its sample or matrix, the analytical method, and the intended role. The context gives the measurement its biomarker job.

**What is the difference between a biomarker and a clinical outcome?**

A biomarker measures a biological characteristic. A clinical outcome assessment directly describes how a person feels, functions, or survives. Some biomarkers may be used as surrogate endpoints when evidence supports that specific role, but the word biomarker alone does not establish clinical benefit. The intended context and level of validation must be stated rather than assumed.

**What is the difference between predictive and prognostic biomarkers?**

A prognostic biomarker indicates the likelihood of a future clinical event, recurrence, or progression in people who already have the condition of interest, without depending on a particular intervention. A predictive biomarker identifies people more likely to experience a favorable or unfavorable effect from a medical product or environmental exposure. One concerns likely course; the other concerns differential response.

**Does FDA biomarker qualification apply to every use of that biomarker?**

No. FDA qualification supports a specific interpretation and application within a stated context of use in medical-product development. It is not a universal approval for every population, purpose, or analytical method. The FDA also distinguishes qualification of the biomarker from qualification of the method used to measure it, so readers should check the exact qualification statement.


---